Overactive Bladder (OAB) Clinical Trial
Official title:
A Prospective, Non-interventional, Registry Study of Patients Initiating Pharmacologic Therapy for Overactive Bladder in Taiwan, Korea and China
The purpose of this study is to observe and describe treatment patterns, like Overactive
Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB
therapies in routine clinical practice.
This study will also evaluate effectiveness of OAB therapies in routine clinical practice;
identify factors associated with effectiveness and persistence of pharmacologic therapies in
OAB participants; evaluate the Quality of Life (QoL) and treatment satisfaction of OAB
therapies; as well as evaluate health care resource utilization (HCRU) and understand adverse
events (AEs), serious adverse events (SAEs) and adverse drug reactions (ADRs) associated with
OAB therapies.
This is an observational registry study and will not provide or recommend any treatment; all decisions regarding treatment are made at the sole discretion of the treating physician in accordance with the treating physician's usual practices and all eligible participants will be enrolled in a certain timeframe. OAB participants enrolled in the study will be categorized into one of two treatment groups, but the study does not plan to compare the two treatment groups. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00507169 -
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
|
Phase 2 | |
| Completed |
NCT02216214 -
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
|
Phase 4 | |
| Completed |
NCT02294396 -
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
|
Phase 4 | |
| Completed |
NCT01936870 -
Drug Use Investigation for Toviaz
|
||
| Completed |
NCT03846895 -
Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)
|
N/A | |
| Completed |
NCT03903094 -
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
|
||
| Terminated |
NCT04451382 -
PTNS vs Botox of Refractory OAB
|
||
| Terminated |
NCT04641975 -
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
|
Phase 3 | |
| Completed |
NCT00366002 -
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
|
Phase 4 | |
| Completed |
NCT02138747 -
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
|
Phase 4 | |
| Completed |
NCT03602508 -
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
|
||
| Completed |
NCT05211193 -
Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).
|
||
| Completed |
NCT04562090 -
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
|
Phase 4 | |
| Completed |
NCT00282932 -
Detrol LA In Men With Overactive Bladder.
|
Phase 4 | |
| Completed |
NCT01639794 -
Vesitirim™ in Men Postmarketing Observational Study
|
N/A | |
| Completed |
NCT00742833 -
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
|
Phase 2 | |
| Withdrawn |
NCT01317810 -
A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
|
N/A |